Compare IRWD & IVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRWD | IVR |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.8M | 758.8M |
| IPO Year | 2009 | 2008 |
| Metric | IRWD | IVR |
|---|---|---|
| Price | $4.10 | $6.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.67 | ★ $8.25 |
| AVG Volume (30 Days) | 1.6M | ★ 2.3M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 17.80% |
| EPS Growth | ★ 1400.00 | 103.08 |
| EPS | ★ 0.55 | 0.10 |
| Revenue | ★ $298,276,000.00 | N/A |
| Revenue This Year | $57.95 | $150.63 |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | ★ $7.40 | $70.70 |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $1.23 | $7.05 |
| 52 Week High | $5.78 | $9.50 |
| Indicator | IRWD | IVR |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 23.54 |
| Support Level | $3.89 | N/A |
| Resistance Level | $4.53 | $8.24 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 8.33 | 6.16 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.